


Annual General Meeting

+



idorsia

Meeting structure


- ① Opening Remarks
- ② Business Review
- ③ Agenda & Proposals

**Mathieu Simon,
Chairman of the Board**

**Jean-Paul Clozel,
Chief Executive Officer**

**Mathieu Simon,
Chairman of the Board**

**Julien Gander,
Secretary of the Board of Directors**





Opening remarks by the Chairman



Brought 3
drugs to the
market

Built a global
marketing
organization

Launched QUVIVIQ
in the US and main
European countries



What have we
achieved in the
past 7 years

Created a late-stage
pipeline and continued
to discover new drugs

Re-acquired
aprocitan from
Johnson & Johnson

Secured financing
for all these
achievements



Opening remarks by the Chairman



Idorsia Executive Committee



Alberto Gimona
Head of Global Clinical
Development & Medical Affairs

Julien Gander
Group General Counsel

André C. Muller
Chief Executive Officer

Martine Clozel
Chief Scientific Officer

Arno Groenewoud
Chief Financial Officer

Working in partnership to guide
Idorsia towards being
a leading biopharmaceutical
company with a strong
scientific core.



Mathieu Simon
Proposed Vice-Chairman
and Lead Independent
Director



Jean-Paul Clozel
Proposed Chairman

Bart Filius

Proposed new Board member



- Member of the Board and Chairman of the Audit Committee of ProQR Therapeutics since 2019.
- Former President of Galapagos: 2021–2023.
- Chief Financial Officer of Galapagos from 2014 adding the role of Chief Operating Officer in 2017.
- Variety of executive positions at Sanofi: 2001–2014,
 - Vice President, Head of Mergers & Acquisitions, Country manager for The Netherlands and Vice President, Chief Financial Officer for Europe.
- Strategy consultant at Arthur D. Little.
- MBA degree from INSEAD, France and a bachelor's degree in business from Nyenrode University, the Netherlands.



Opening remarks by the Chairman



Indonesia

Business Review





Transaction with
Nxera Pharma
CHF 400 million


Recent impactful events



Viatrix partnership
for selatogrel and
cenerimod



Reacquired worldwide
rights for aprocitentan



Approval for
TRYVIO



Cost reduction
at headquarters
with adapted
portfolio



Adapted convertible
bonds 2024 – time to
extend cash runway

QUVIVIQ™ (daridorexant)


QUVIVIQ™
daridorexant 25mg, 50mg
tablets



Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union, in Switzerland and in Canada.

Expanding access & availability

QUvivIQ[™]
daridorexant 25mg, 50mg
tablets



Scheduling under discussion



Citizen's Petition
requesting de-scheduling
of the DORA class
of medicines
progressing

Daridorexant is available in the US, Germany, Italy, Spain, Switzerland, the UK and Canada under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union.

Unlocking value for Idorsia

Exploring best avenues to maximize aprocitentan value



TRYVIO™ (aprocitentan)
12.5 mg approved in
March 2024



JERAYGO™ (aprocitentan)
12.5 mg & 25 mg
recommended in April 2024



TRYVIO™
(aprocitentan) 12.5mg tablets




JERAYGO™
aprocitentan

Aprocitentan is only approved in the US under the tradename TRYVIO™ where it will be made available later in 2024. Market authorization is under review in other countries.



**Continue to increase
sales of QUVIVIQ**



**Prepare for the launch
of TRYVIO in the US**



**What needs
to be done
this year**



Continue to innovate



Extend the cash runway



Be prepared for more...

2024 – The start of a new
phase for Idorsia





Concluding remarks by the Chairman





Be prepared
for more

